Novartis Ireland Limited

Lobbying Organisation Novartis Ireland Limited

Date published 18 Sep, 2024

Relevant Matter Matters involving public funds

Public Policy Area Health

Period 1 May, 2024 to 31 Aug, 2024

Specific Details Access in Heart Failure (HF) & healthcare system readiness for new medicine platforms like radioligand therapies. Clinical trial attractiveness

Intended results Heart Failure (HF) patients can be prescribed an ARNI (Entresto) based on ESC guidelines, in line with HF patients in other EU countries. The healthcare system needs to get ready for new medicine platforms like radioligand therapies. Importance of Ireland being competitive with regard to attractive clinical trials to Ireland.

Name of person primarily responsible for lobbying on this activity Caitriona Walsh (Managing Director) Kate Barton (Corporate Affairs) Susanne O'Reilly (Public Affairs Head)

Did any Designated Public Official(DPO) or former Designated Public Official(DPO) carry out lobbying activities on your behalf in relation to this return? You must include yourself, and answer Yes, if you are a current DPO or a DPO at any time in the past. (What is a Designated Public Official?) No

Did you manage or direct a grassroots campaign? No

Was this lobbying done on behalf of a client? No

Lobbying activity

The following activities occurred for this specific Subject Matter Area.

Email (2-5)

Emails setting up meetings. Briefing with regard to clinical trials in Ireland.

Meeting (2-5)

Designated public officials lobbied

The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.

Duncan Smith TD (Dáil Éireann, the Oireachtas)

John Lahart TD (Dáil Éireann, the Oireachtas)